Working in partnership to advance the 3Rs in toxicity testing

Toxicology

Volumn 267, Issue 1-3, 2010, Pages 14-19

  Holmes, Anthony M ^a   Creton, Stuart ^a   Chapman, Kathryn ^a  

^a National Centre for the Replacement   (United Kingdom)

Author keywords

3Rs; Acute toxicity; Monoclonal antibodies; Primates; Safety testing; Toxicokinetics

Indexed keywords

CHEMICAL COMPOUND; MONOCLONAL ANTIBODY;

ANIMAL TESTING REDUCTION; ANIMAL TESTING REFINEMENT; ANIMAL TESTING REPLACEMENT; CHEMICAL INDUSTRY; DRUG INDUSTRY; EXPERIMENTAL ANIMAL WELFARE; GOVERNMENT REGULATION; HEALTH CARE PLANNING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING; TOXICOKINETICS; UNITED KINGDOM;

ANIMAL EXPERIMENTATION; ANIMAL HUSBANDRY; ANIMAL TESTING ALTERNATIVES; ANIMAL WELFARE; COOPERATIVE BEHAVIOR; DRUG INDUSTRY; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; TOXICITY TESTS;

ANIMALIA; PRIMATES;

EID: 71949116166     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2009.11.006     Document Type: Review

References (32)

1. Anon. The Innovative Medicines Initiative (IMI) Strategic Research Agenda (2006), European Federation of Pharmaceutical Industries and Associations
2. Balls M. Why modification of the LD50 test will not be enough. Lab Anim. 25 (1991) 198-206
3. Barton H.A., Pastoor T.P., Baetcke K., Chambers J.E., Diliberto J., Doerrer N.G., Driver J.H., Hastings C.E., Iyengar S., Krieger R., Stahl B., and Timchalk C. The acquisition and application of absorption, distribution, metabolism, and excretion (ADME) data in agricultural chemical safety assessments. Crit. Rev. Toxicol. 36 (2006) 9-35
4. Basketter D.A., Reynolds F.S., and York M. Predictive testing in contact dermatitis. Irritant dermatitis. Clin. Dermatol. 15 (1997) 637-644
5. Chapman, K., Pullen, N., Coney, L., Dempster, M., Andrews, L., Bajramovich, J., Baldrick, P., Buckley, L., Jacobs, A., Hale, G., Green, C., Ragan, I., Robinson, V., 2009. Preclinical development of monoclonal antibodies: considerations for the use of nonhuman primates. mAbs. 1, 505-516.
6. Chapman K., Pullen N., Graham M., and Ragan I. Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat. Rev. Drug Discov. 6 (2007) 120-126
7. Creton S., Billington R., Davies W., Dent M., Hawksworth G., Parry S., and Travis K. Application of toxicokinetics to improve chemical risk assessment: implications for the use of animals. Regul. Toxicol. Pharmacol. 55 (2009) 291-299
8. Creton, S., Dewhurst, I.C., Earl, L.K., Gehen, S.C., Guest, R., Hotchkiss, J.A., Indans, I., Woolhiser, M.R., Billington, R., 2009b. Acute toxicity testing of chemicals-opportunities to avoid redundant testing and use alternative approaches. Crit. Rev. Toxicol., in press.
9. EC. Directive 2003/15/EC of the European Parliament and of the Council of 27 February 2003 amending Council Directive 76/768/EEC on the approximation of the laws of the member states relating to cosmetic products'. European Commission. Off. J. Eur. Union L66 (2003) 26-35
10. EC. Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restrictions of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC. Off. J. Eur. Union L396 (2006) 1-849
11. ESAC, 2008. Statement on the Scientific Validity of In-Vitro Tests for Skin Irritation Testing. http://ecvam.jrc.it/index.htm.
12. FDA, 2004. Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf.
13. Fentem J.H., and Botham P.A. ECVAM's activities in validating alternative tests for skin corrosion and irritation. Altern. Lab Anim. 30 Suppl 2 (2002) 61-67
14. Hartung T., and Rovida C. Chemical regulators have overreached. Nature 460 (2009) 1080-1081
15. Holmes A.M., Brown R., and Shakesheff K. Engineering tissue alternatives to animals: applying tissue engineering to basic research and safety testing. Regen. Med. 4 (2009) 579-592
16. Home Office, 2009. Statistics of Scientific Procedures on Living Animals: Great Britain 2008. http://www.homeoffice.gov.uk/rds/pdfs09/spanimals08.pdf.
17. ICH, 2008. Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals S6. www.ich.org.
18. ICH, 2009. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals ICH M3(R2). http://www.ich.org.
19. Jagger C., Tate M., Cahill P.A., Hughes C., Knight A.W., Billinton N., and Walmsley R.M. Assessment of the genotoxicity of S9-generated metabolites using the GreenScreen HC GADD45a-GFP assay. Mutagenesis 24 (2009) 35-50
20. Langley, G., 2005. Acute toxicity testing without animals. ECEAE. http://www.eceae.org/downloads/pdf/ECEAE_Acute_Toxicity.pdf.
21. Maxwell G., and Mackay C. Application of a systems biology approach for skin allergy risk assessment. AATEX 14 (2008) 381-388
22. NC3Rs, 2007. Challenging the regulatory requirement for acute toxicity studies in the development of new medicines: a workshop report. http://www.nc3rs.org.uk/downloaddoc.asp?id=559&page=22&skin=0.
23. NC3Rs, 2009a. Animals in the chemical industry. www.nc3rs.org.uk/chemicals.
24. NC3Rs, 2009b. Encouraging commercialisation of tissue engineering-a speed-networking event. www.nc3rs.org.uk/speednetworking.
25. NC3Rs, 2009c. Funded small awards. www.nc3rs.org.uk/page.asp?id=290.
26. NRC. Toxicity Testing in the 21st Century: A Vision and a Strategy (2007), National Academy Press, Washington, DC
27. Robinson M.K., Cohen C., De Fraissinette Ade B., Ponec M., Whittle E., and Fentem J.H. Non-animal testing strategies for assessment of the skin corrosion and skin irritation potential of ingredients and finished products. Food Chem. Toxicol. 40 (2002) 573-592
28. Robinson S., and Chapman K. Are acute toxicity studies required to support overdose for new medicines?. Regul. Toxicol. Pharmacol. 55 (2009) 110
29. Robinson S., Delongeas J.L., Donald E., Dreher D., Festag M., Kervyn S., Lampo A., Nahas K., Nogues V., Ockert D., Quinn K., Old S., Pickersgill N., Somers K., Stark C., Stei P., Waterson L., and Chapman K. A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development. Regul. Toxicol. Pharmacol. 50 (2008) 345-352
30. Saghir S.A., Mendrala A.L., Bartels M.J., Day S.J., Hansen S.C., Sushynski J.M., and Bus J.S. Strategies to assess systemic exposure of chemicals in subchronic/chronic diet and drinking water studies. Toxicol. Appl. Pharmacol. 211 (2006) 245-260
31. Westmoreland C., and Holmes A.M. Assuring consumer safety without animals: applications for tissue engineering. Organogenesis 5 (2009) 67-72
32. Zhao B., Ma A., Martin F.L., and Fullwood N.J. An investigation into corneal alkali burns using an organ culture model. Cornea 28 (2009) 541-546